Page last updated: 2024-09-05

sorafenib and ubenimex

sorafenib has been researched along with ubenimex in 3 studies

Compound Research Comparison

Studies
(sorafenib)
Trials
(sorafenib)
Recent Studies (post-2010)
(sorafenib)
Studies
(ubenimex)
Trials
(ubenimex)
Recent Studies (post-2010) (ubenimex)
6,5207305,25193043182

Protein Interaction Comparison

ProteinTaxonomysorafenib (IC50)ubenimex (IC50)
Aminopeptidase BRattus norvegicus (Norway rat)6
M1 family aminopeptidasePlasmodium falciparum FcB1/Columbia0.284
Cytosol aminopeptidaseBos taurus (cattle)1.0005
72 kDa type IV collagenaseHomo sapiens (human)6.45
Leukotriene A-4 hydrolaseHomo sapiens (human)1.4742
Aminopeptidase NHomo sapiens (human)2.6333
Aminopeptidase NSus scrofa (pig)3.8211
Angiotensin-converting enzymeRattus norvegicus (Norway rat)2.7
Puromycin-sensitive aminopeptidaseHomo sapiens (human)3.5
Bacterial leucyl aminopeptidaseVibrio proteolyticus1.0005

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ1
Asaoka, T; Doki, Y; Eguchi, H; Gotoh, K; Kawamoto, K; Mori, M; Noda, T; Ogawa, H; Umeshita, K; Wada, H; Yamada, D; Yamashita, M1
Ding, S; Gao, D; Gao, M; Liu, S; Lv, J; Niu, Z; Wang, X; Wang, Z1

Other Studies

3 other study(ies) available for sorafenib and ubenimex

ArticleYear
Identification of potent Yes1 kinase inhibitors using a library screening approach.
    Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15

    Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship

2013
A CD13 inhibitor, ubenimex, synergistically enhances the effects of anticancer drugs in hepatocellular carcinoma.
    International journal of oncology, 2016, Volume: 49, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; CD13 Antigens; Cell Cycle; Cell Line, Tumor; Cisplatin; Drug Synergism; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Leucine; Liver Neoplasms; Neoplastic Stem Cells; Niacinamide; Phenylurea Compounds; Reactive Oxygen Species; Sorafenib

2016
Ubenimex attenuates acquired sorafenib resistance in renal cell carcinoma by inhibiting Akt signaling in a lipophagy associated mechanism.
    Oncotarget, 2016, Nov-29, Volume: 7, Issue:48

    Topics: Adenine; Animals; Autophagy; Carcinoma, Renal Cell; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Kidney Neoplasms; Leucine; Lipid Metabolism; Mice; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-akt; Signal Transduction; Sorafenib; Xenograft Model Antitumor Assays

2016